Clinical Trial Update: Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 study evaluating atezolizumab in combination with immunogenic chemotherapy for metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Oslo University Hospital | Conditions: Cancer, Breast, Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED